Reposted by Pidgin, Kell of House Hemangioblastoma

GOOD NEWS! Phase I clinical trial results show a first-of-its-kind personalized vaccine designed to treat glioblastoma, a deadly and aggressive form of brain cancer, is safe AND elicits robust and broad immune responses that appears to INCREASE recurrence-free survival in patients after surgery.